Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2019 /
5' UTR mutations in prostate cancer

29th Mar - 3rd Apr 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.04.19
Views: 1272

Dr Yiting Lim, Fred Hutchinson Cancer Research Center, Seattle, USA

Dr Yiting Lim speaks to ecancer at the 2019 American Association for Cancer Research (AACR) meeting about the 5' UTR mutations that are present among the DNA of prostate cancer patients.

Dr Lim emphasises the significance of this research, as mutations in the 5' UTR are often overlooked and require more research. 

By using publically available datasets, localised patient DNA was examined for 5' UTR mutations.
The group also sequenced genomic DNA acquired from patients with metastatic castration-resistant prostate cancer. The somatic mutations identified (mostly SNPs, but some short insertions/deletions) were found to be recurrent within the whole patient cohort.

Dr Lim states that the results of this study suggest the importance of post-transcriptional regulation potential therapies should focus on mechanisms around this. She also mentions the possibility of personalising these treatments to target a patient's specific mutations.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation